The exemption that runs to November 27, 2027 was not granted in isolation. FDA tied it to a piece of work it is carrying out on whether package-level tracing is workable for small pharmacies, and that work has a participation deadline much sooner than 2027.
What the assessment is for
FDA states the exemption allows time to complete an assessment of small dispensers, publish the final assessment report for public comment, and hold a public meeting on it. In other words, the extension exists so the agency can find out what small dispensers are actually able to implement.
The survey
FDA encouraged small dispensers to complete the assessment survey by September 22, 2026. Small dispensers may designate another party, such as a consultant, to complete it on their behalf.
This is the point in the process where a small pharmacy has direct input. The report and the public meeting that follow will be informed by what the agency hears here.
Why it is worth your attention
- The assessment findings will inform what obligations look like after the exemption ends
- Participation is the mechanism for small pharmacies to describe real operational constraints
- The final report goes out for public comment, so there is a second opportunity to respond
If your pharmacy qualifies as a small dispenser, this is a short piece of work with a long shelf life. The alternative is having the feasibility question answered without your input.
Which DSCSA deadlines apply to youThe employee threshold and what the exemption covers.This article is provided for general information only and is not legal or regulatory advice. Requirements depend on your specific circumstances and change over time. Consult the current FDA guidance and your own counsel or compliance advisor before acting on it.